Palak Choksi1, Brittany L Gay1, David Reyes-Gastelum1, Megan R Haymart1, Maria Papaleontiou2. 1. From the Division of Metabolism, Endocrinology and Diabetes, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan. 2. From the Division of Metabolism, Endocrinology and Diabetes, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan.. Electronic address: mpapaleo@med.umich.edu.
Abstract
OBJECTIVE: To understand osteoporosis screening practices, particularly in men, by a diverse cohort of physicians, including primary care physicians, endocrinologists, and geriatricians. METHODS: We surveyed randomly selected members of the American Academy of Family Practice, Endocrine Society, and American Geriatrics Society. Respondents were asked to rate how often they would screen for osteoporosis in four different clinical scenarios by ordering a bone density scan. Multivariable logistic regression analyses were conducted to determine factors associated with offering osteoporosis screening in men in each clinical scenario. Physicians were also asked to note factors that would lead to osteoporosis screening in men. RESULTS: Response rate was 63% (359/566). While 90% respondents reported that they would always or frequently screen for osteoporosis in a 65-year-old post-menopausal woman, only 22% reported they would screen a 74-year-old man with no significant past medical history. Endocrinologists were more likely to screen a 74-year-old man compared to primary care physicians (odds ratio, 2.32; 95% confidence interval, 1.10 to 4.88). In addition to chronic steroid use (94%), history of nontraumatic fractures (88%), and androgen-deprivation therapy for prostate cancer (82%), more than half the physicians reported suppressive doses of thyroid hormone (64%) and history of falls (52%) as factors leading to screening for osteoporosis in men. CONCLUSIONS: Our survey results highlight heterogeneity in osteoporosis screening in men, with underscreening in some scenarios compared to women, and identify factors that lead to screening in men. These findings can help design interventions to improve osteoporosis screening in men.
OBJECTIVE: To understand osteoporosis screening practices, particularly in men, by a diverse cohort of physicians, including primary care physicians, endocrinologists, and geriatricians. METHODS: We surveyed randomly selected members of the American Academy of Family Practice, Endocrine Society, and American Geriatrics Society. Respondents were asked to rate how often they would screen for osteoporosis in four different clinical scenarios by ordering a bone density scan. Multivariable logistic regression analyses were conducted to determine factors associated with offering osteoporosis screening in men in each clinical scenario. Physicians were also asked to note factors that would lead to osteoporosis screening in men. RESULTS: Response rate was 63% (359/566). While 90% respondents reported that they would always or frequently screen for osteoporosis in a 65-year-old post-menopausal woman, only 22% reported they would screen a 74-year-old man with no significant past medical history. Endocrinologists were more likely to screen a 74-year-old man compared to primary care physicians (odds ratio, 2.32; 95% confidence interval, 1.10 to 4.88). In addition to chronic steroid use (94%), history of nontraumatic fractures (88%), and androgen-deprivation therapy for prostate cancer (82%), more than half the physicians reported suppressive doses of thyroid hormone (64%) and history of falls (52%) as factors leading to screening for osteoporosis in men. CONCLUSIONS: Our survey results highlight heterogeneity in osteoporosis screening in men, with underscreening in some scenarios compared to women, and identify factors that lead to screening in men. These findings can help design interventions to improve osteoporosis screening in men.
Authors: Amir Qaseem; Vincenza Snow; Paul Shekelle; Robert Hopkins; Mary Ann Forciea; Douglas K Owens Journal: Ann Intern Med Date: 2008-05-06 Impact factor: 25.391
Authors: Susan J Curry; Alex H Krist; Douglas K Owens; Michael J Barry; Aaron B Caughey; Karina W Davidson; Chyke A Doubeni; John W Epling; Alex R Kemper; Martha Kubik; C Seth Landefeld; Carol M Mangione; Maureen G Phipps; Michael Pignone; Michael Silverstein; Melissa A Simon; Chien-Wen Tseng; John B Wong Journal: JAMA Date: 2018-06-26 Impact factor: 56.272
Authors: Adrianne C Feldstein; Gregory Nichols; Eric Orwoll; Patricia J Elmer; David H Smith; Michael Herson; Mikel Aickin Journal: Osteoporos Int Date: 2005-06-01 Impact factor: 4.507
Authors: R B Hopkins; E Pullenayegum; R Goeree; J D Adachi; A Papaioannou; W D Leslie; J E Tarride; L Thabane Journal: Osteoporos Int Date: 2011-05-11 Impact factor: 4.507
Authors: C Cooper; Z A Cole; C R Holroyd; S C Earl; N C Harvey; E M Dennison; L J Melton; S R Cummings; J A Kanis Journal: Osteoporos Int Date: 2011-04-02 Impact factor: 4.507
Authors: Nelson B Watts; Robert A Adler; John P Bilezikian; Matthew T Drake; Richard Eastell; Eric S Orwoll; Joel S Finkelstein Journal: J Clin Endocrinol Metab Date: 2012-06 Impact factor: 5.958
Authors: Sian Yik Lim; Joon Hee Lim; Dan Nguyen; Rie Okamura; Hoda Mojazi Amiri; Michael Calmes; Kenneth Nugent Journal: Am J Mens Health Date: 2013-02-25